Pharmacy Daily | Sigma records 41% EBIT growth in FY25

SIGMA recorded normalised EBIT growth of 41% and statutory net profit after tax of $529.9 million in its first post-merger end-of-year results, according to an ASX statement this morning.

Key figures include like-for-like sales growth of 11.3% across the Australian Chemist Warehouse network, which now comprises 588 stores.

"The merger with Chemist Warehouse has delivered a stronger, more integrated healthcare business, with greater scale, capability, and market reach," said Sigma CEO and Managing Director Vikesh Ramsunder.

"The FY25 results demonstrate the group's momentum and potential for ongoing growth.

"Normalised EBIT for the year was up 41.4% compared to the prior corresponding period."

Ramsunder said supply chain reliability and efficiencies were key to the group's success, with the benefit of scale resulting savings of 11% per unit cost to serve.

The Sigma group now has 881 franchise stores across Australia, and reported 35 new stores in Australia and internationally in FY25.

"Sigma is now a stronger more integrated healthcare business - one with scale, capability, market reach and growth pathways," Ramsunder said.

"We have just started the journey to fully realise the benefits of the merger," he concluded.

Sigma also announced that CFO Mark Davis will be stepping down, and Damien Gance has resigned from his role as Chief Strategy and Business Development Officer.

In addition, Chemist Warehouse COO Mario Tascone has been appointed Deputy CEO of Retail across the combined group.

"This was the first earnings release after the Chemist Warehouse merger in Feb and the results highlighted the potential success of the partnership," Jamie Hannah of investment management firm VanEck told Pharmacy Daily.

"The results showcased an increase in earning over 30%, significant cost reductions up to $100m and changes to senior management," he explained, adding that "the outlook was also positive with expectations to deliver solid sales growth". KB